← All Cell Source, INC filings

Cell Source, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

OTC.Pink
CLCS
Cell Source, INC
10-Q: Cell Source, Inc. Q1 2025 Update: Net Loss Widens Amidst Funding Efforts
Cell Source, Inc. reported a net loss of $1.48 million for Q1 2025, with significant increases in R&D expenses and interest costs, while actively pursuing capital raises to address going concern issues.
OTC.Pink
CLCS
Cell Source, INC
10-Q: Cell Source Inc. Reports Third Quarter 2024 Results Amidst Financial Challenges
Cell Source Inc. reports a net loss of $4.18 million for the nine months ended September 30, 2024, alongside ongoing efforts to secure additional funding.
OTC.Pink
CLCS
Cell Source, INC
10-Q: Cell Source Inc. Reports Continued Losses in Q2 2024, Citing Going Concern Uncertainty
Cell Source Inc. reports a net loss of $2.76 million for the first six months of 2024 and expresses substantial doubt about its ability to continue as a going concern.
OTC.Pink
CLCS
Cell Source, INC
10-Q: Cell Source Inc. Reports Q1 2024 Results: Funding Concerns Loom Amidst Ongoing Development
Cell Source Inc. reports a net loss for Q1 2024 and expresses concerns about its ability to continue as a going concern due to a working capital deficiency and past due notes.